Charles Bird, MD
Family Medicine · Colorado Spgs, CONPI 1134164718
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,185 of the $5,420 with a category attached, or 77.2%. 41 manufacturers reported payments, led by Merck at 27.8% of the total. Among family medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 248 payments — averaging $21.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- Boehringer Ingelheim$544
- AstraZeneca$484
- Lilly USA, LLC$320
- Amgen$278
- AbbVie$267
- plus $2K from 35 others
Across 63 payments — averaging $7517.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$218K
- Eli Lilly$142K
- AstraZeneca$55K
- Amgen$38K
- Astrazeneca UK Limited$12K
- Pfizer$9K
What the payments were for
- Travel & lodging$1,23423%
- Food & beverage$4,18577%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 11 | $1,505 |
| Boehringer Ingelheim | 29 | $544 |
| AstraZeneca | 26 | $484 |
| Lilly USA, LLC | 27 | $320 |
| Amgen(2 entities) | 18 | $278 |
| AbbVie(2 entities) | 22 | $267 |
| Johnson & Johnson | 15 | $259 |
| E.r. Squibb & Sons, L.L.C. | 10 | $176 |
| Astellas Pharma US Inc | 8 | $160 |
| Esperion Therapeutics, Inc. | 8 | $152 |
| Pfizer | 8 | $149 |
| GSK | 6 | $133 |
| Eisai Inc. | 6 | $101 |
| Sanofi-aventis U.S. LLC | 5 | $81 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $73 |
| Kowa Pharmaceuticals America, Inc. | 5 | $65 |
| Nevro Corp. | 2 | $54 |
| Daiichi Sankyo Inc. | 3 | $52 |
| Genentech USA, Inc. | 3 | $52 |
| Novartis | 2 | $46 |
| Amarin Pharma, Inc. | 2 | $41 |
| Abbott | 2 | $39 |
| Optinose US, Inc. | 2 | $38 |
| Hologic Sales And Service, LLC | 2 | $36 |
| Novo Nordisk | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Bausch Health US, LLC | 2 | $26 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 2 | $24 |
| Biogen | 1 | $19 |
| Bayer | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Grifols USA, LLC | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $15 |
| Mannkind Corporation | 1 | $15 |
| Radius Health, Inc. | 1 | $13 |
| Vertiflex, Inc. | 1 | $12 |
| Clarus Therapeutics Inc. | 1 | $12 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
How this compares
$5,420 in reported general payments places this provider in the 95th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 103 | $123,483 |
| JardianceEmpagliflozin | 62 | $85,616 |
| OzempicSemaglutide | 42 | $63,038 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $31,950 |
| ProliaDenosumab | 14 | $23,775 |
| MyrbetriqMirabegron | 19 | $20,357 |
| XareltoRivaroxaban | 12 | $19,334 |
| JanuviaSitagliptin Phosphate | 17 | $15,110 |
| DayvigoLemborexant | 14 | $4,593 |
| Rosuvastatin Calcium | 281 | $4,210 |
| Levothyroxine Sodium | 294 | $3,492 |
| Ezetimibe | 115 | $2,962 |
| Atorvastatin Calcium | 230 | $2,527 |
| Raloxifene Hcl | 34 | $2,401 |
| Amlodipine-AtorvastatinAmlodipine/Atorvastatin | 13 | $2,365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $149 | $123,483103 claims |
| Boehringer IngelheimJardiance | $544 | $85,61662 claims |
| Novo NordiskOzempic | $30 | $63,03842 claims |
| AstraZenecaBreztri Aerosphere | $484 | $31,95023 claims |
| AmgenProlia | $278 | $23,77514 claims |
| Astellas Pharma US IncMyrbetriq | $160 | $20,35719 claims |
| Johnson & JohnsonXarelto | $259 | $19,33412 claims |
| MerckJanuvia | $1,505 | $15,11017 claims |
| Eisai Inc.Dayvigo | $101 | $4,59314 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $3,492294 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Colorado Spgs
- Ethan LazarusDenver$688K
- Michael de NardisLarkspur$335K
- Matthew YoungColorado Springs$270K
- Mark DeutchmanDenver$258K
- Kari UusinarkausWoodland Park$254K
- Michael MeekerUsaf Academy$174K
- Carolynn Francavilla BrownLakewood$174K
- Lawrence AndrewsColorado Springs$102K
- Gregory MaederWestminster$95K
- Paul SimmonsGrand Junction$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.